Weight Loss Drugs: May Reduce Addiction & Overdose Risk – Study Finds

The emerging story around weight-loss drugs like Mounjaro and Ozempic is taking another unexpected turn. New research suggests these medications, initially developed for type 2 diabetes and obesity, may also reduce the risk of developing substance use disorders – and even lessen the danger for those already struggling with addiction. The findings, published in the British Medical Journal, add to a growing body of evidence hinting at a broader impact of these drugs than previously understood.

How GLP-1s Might Influence Addiction Risk

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Mounjaro and Ozempic, work by mimicking a natural hormone that regulates blood sugar. But their influence doesn’t stop there. Researchers believe these drugs impact the brain’s reward pathways, potentially reducing cravings and compulsive behaviors associated with addiction. They also promote a feeling of fullness, which could indirectly lessen the drive to seek reward through substances. As Health.com explains, these drugs belong to a class known as incretin mimetics, mimicking the effects of naturally occurring hormones.

The US study analyzed data from over 606,000 US veterans with type 2 diabetes, tracking their substance use patterns for up to three years. The results showed a notable reduction in risk among those taking GLP-1s compared to those on other diabetes medications. Specifically, GLP-1s were associated with an 18% lower risk of alcohol-related disorders in individuals with no prior history of substance use. Reductions were also observed for cannabis (14%), cocaine (20%), nicotine (20%), and opioids (25%).

Beyond Prevention: Reducing Harm for Existing Addiction

The potential benefits extend beyond preventing new addictions. The study also indicated that GLP-1s could significantly reduce the risks associated with existing substance use. Individuals already using substances experienced a 39% lower risk of overdose, a 31% reduction in emergency department visits, and a remarkable 50% decrease in mortality. This suggests these medications could be a valuable tool in harm reduction strategies.

However, experts caution against interpreting these findings as definitive proof of a causal link. Prof Claire Anderson, president of the Royal Pharmaceutical Society, emphasized that this was an observational study, meaning it cannot definitively prove that GLP-1s prevent or treat addiction. “Further research, including clinical trials, will be needed to understand whether GLP-1 medicines have a direct effect,” she stated. Lilly’s Mounjaro website highlights that it is the first GIP and GLP-1 receptor agonist approved for improving glycemic control in adults with type 2 diabetes.

Weight Regain and Stigma: Complicating the Picture

While the potential benefits are intriguing, it’s crucial to acknowledge the challenges associated with these medications. Recent research, published in the journal eClinical Medicine, reveals that most people who stop taking GLP-1s regain a significant portion of the weight they lost. A meta-analysis of 48 studies found that individuals typically regain 60% of lost weight within a year, and 75% within two years, ultimately sustaining only about 25% of the initial weight loss long-term. This highlights the demand for ongoing support and lifestyle changes to maintain weight loss.

Adding to the complexity, a survey by Simple Online Pharmacy found that two-thirds of patients taking GLP-1s hide their use from friends and family, fearing judgment and accusations of “cheating.” Nearly 40% reported being criticized for using the drugs, with many accused of taking “the straightforward way out” or told to simply “eat less and move more.” This stigma surrounding weight-loss medications can create barriers to access and adherence.

The NHS Rollout and Broader Implications

Despite the potential benefits, the rollout of these drugs within the UK’s National Health Service (NHS) remains “painfully slow,” according to Gareth Jones, director of corporate affairs at the National Pharmacy Association. What we have is particularly concerning given the significant health problems associated with obesity. Jones emphasized that understanding the long-term impact of GLP-1s is ongoing, but that weight loss treatment can have a positive effect on a range of health outcomes for eligible patients.

The findings raise important questions about the potential for repurposing these medications beyond their initial indications. Could GLP-1s turn into part of a broader strategy for preventing and treating addiction? Further research is needed to explore this possibility, including well-designed clinical trials to assess efficacy and safety.

What’s Next for GLP-1 Research and Access?

The current research landscape points to several key areas for future investigation. Larger, randomized controlled trials are needed to confirm the observed associations between GLP-1s and reduced substance use risk. These trials should also investigate the underlying mechanisms by which these drugs might influence reward pathways and craving behavior. Researchers will also need to explore the optimal duration of treatment and the potential for long-term benefits. Finally, addressing the stigma surrounding these medications and ensuring equitable access to treatment will be crucial for maximizing their potential impact. Drugs.com provides a comparison of Mounjaro and Ozempic, noting that Mounjaro works at both the GIP and GLP-1 receptors, while Ozempic only binds to GLP-1 receptors.